1. Targeting Thyroid Cancer

2. Program Goal

3. Thyroid Cancer Newly Detected 2013 (n=60,220)

4. Follicular Cell Thyroid Cancer Deaths 2013 (n = 1850)

5. Familial Syndromes

6. Thyroid Cancer Treatment “Pyramid”

7. Risk Stratification

10. RAI-Refractory Disease

11. Doxorubicin: Single-agent Activity

12. Doxorubicin +/- Cisplatin

13. Doxorubicin +/- Cisplatin: Results

15. Targets in Thyroid Cancer

16. VEGF and Thyroid Cancer

17. Sorafenib

18. Sorafenib University of Pennsylvania

19. Sorafenib Results University of Pennsylvania

20. Sorafenib Ohio State

21. Sorafenib Results Ohio State

22. Sorafenib Response Rates Ohio State vs Penn

23. DECISION Study

24. DECISION Study Results

25. DECISION Study Response Rates

26. Lenvatinib (E7080) Background

27. Lenvatinib Response Rate

28. Differentiated Thyroid Cancers Phase 2 Studies -- Multitargeted TKIs

29. Summary of Angiogenesis Inhibition

30. Genetic Alterations in Thyroid Cancer

31. Concordance of Genetic Alterations in MAPK but Not PI3K Pathway Oncogenes

32. Selumetinib (AZD6244)

33. Selumetinib Response Rate

35. Impact of Selumetinib on 124I Incorporation

37. Responses for RAI-Treated Patients

38. BRAF

39. Vemurafenib

40. Vemurafenib Response Rate

41. Current Studies for BRAF Mutant Thyroid Cancer

42. Summary of BRAF and MEK targets

43. Medullary Thyroid Cancer

44. Presentations of MCT

45. MTC: Hereditary vs Sporadic?

46. Hereditary MTC Until Proven Otherwise

47. Sporadic MTC Frequency of RET Mutations

48. Vandetanib (ZD6474)

49. Vandetanib: Randomized Phase 3 Trial

50. Vandetanib: PFS

51. Vandetanib: Objective Tumor Assessments

52. Cabozantinib (XL184)

53. Cabozantinib: Phase 3 Study Design (EXAM)

54. Cabozantinib: PFS

55. Summary of Medullary Thyroid Cancer

56. Abbreviations

57. Abbreviations (cont)

58. Abbreviations (cont)

59. References

60. References (cont)

61. References (cont)

62. References (cont)

63. References (cont)

64. References (cont)

65. References (cont)